昊帆生物: management transactions · France · AMF SZSE:301393 FR FR · AMF Mcap 5.5Bn€
Browse the full management transaction log of 昊帆生物, a listed equity based in France. Shares trade on FR FR, under the authority of AMF. Market capitalisation: €5.5bn. The latest transaction was filed on 18 July 2024 — Purchase. Among the most active insiders: 徐杰. All data is free.
Financial data FY ended December 2025 · cache
Income statement
Revenue 602.3 M€
Gross profit 209.8 M€ 35% margin
Net income 114.7 M€ 19.0% margin
Balance sheet & cash
Market cap 5.47 Bn€
Total debt 51.3 M€
Free Cash Flow −133.0 M€
Last declaration on 18 July 2024
Declarations 10 total
Executives ● Purchase8 SZSE
15,700 shares
SZSE:173000007860432400 · 18 Jul 2024
Ideal exit: 14 Apr 2025 (T+270) Executives ● Purchase8 SZSE
17,200 shares
SZSE:173000007855017470 · 17 Jul 2024
Ideal exit: 13 Apr 2025 (T+270) Executives ● Purchase19 SZSE
33,000 shares
SZSE:173000007855017500 · 17 Jul 2024
Ideal exit: 13 Apr 2025 (T+270) Executives ● Purchase26 SZSE
32,400 shares
SZSE:173000007850847460 · 16 Jul 2024
Ideal exit: 12 Apr 2025 (T+270) Executives ● Purchase8 SZSE
1,000 shares
SZSE:173000007834077100 · 10 Jul 2024
Ideal exit: 6 Apr 2025 (T+270) Executives ● Purchase8 SZSE
9,000 shares
SZSE:173000007830646750 · 9 Jul 2024
Ideal exit: 5 Apr 2025 (T+270) Executives ● Purchase12 SZSE
13,000 shares
SZSE:173000007830646720 · 9 Jul 2024
Ideal exit: 5 Apr 2025 (T+270) Executives ● Purchase12 SZSE
97,100 shares
SZSE:173000007827720500 · 8 Jul 2024
Ideal exit: 4 Apr 2025 (T+270) Executives ● Purchase8 SZSE
8,300 shares
SZSE:173000007819032220 · 4 Jul 2024
Ideal exit: 31 Mar 2025 (T+270) Executives ● Purchase8 SZSE
9,000 shares
SZSE:173000007819032200 · 4 Jul 2024
Ideal exit: 31 Mar 2025 (T+270)
